Short-, long-course therapy comparable in T3 rectal cancer

September 27, 2012
Short-, long-course therapy comparable in T3 rectal cancer
There are no statistically significant differences in the rates of local recurrence, distant recurrence, relapse-free survival, overall survival, or late toxicity in patients treated with short-course radiotherapy or long-course chemoradiation, according to research published online Sept. 24 in the Journal of Clinical Oncology.

(HealthDay)—There are no statistically significant differences in the rates of local recurrence (LR), distant recurrence, relapse-free survival, overall survival, or late toxicity in patients treated with short-course (SC) radiotherapy or long-course (LC) chemoradiation, according to research published online Sept. 24 in the Journal of Clinical Oncology.

Samuel Y. Ngan, M.D., of the Peter MacCallum Cancer Centre in Melbourne, Australia, and colleagues conducted a study involving 326 patients with T3N0-2M0 rectal adenocarcinoma to compare the LR rate between SC and LC neoadjuvant radiotherapy for rectal cancer. SC consisted of pelvic radiotherapy, early surgery, and six courses of adjuvant chemotherapy, while LC included with continuous infusional fluorouracil, followed by surgery and four chemotherapy courses.

The researchers found the three-year LR rates to be 7.5 and 4.4 percent for SC and LC, respectively. Five-year distant recurrence rates were 27 and 30 percent for SC and LC, respectively. Overall five-year were 74 versus 70 percent. Finally, late toxicity rates were not substantially different for SC- and LC-treated patients. None of these differences were statistically significant.

"The trial data indicate that LC may be more effective than SC in reducing the risk of LR, especially for distal tumors," the authors write. "However, we have not been able to definitively determine that such a difference does exist, and further study would be required to help clarify this issue."

One author disclosed to pharmaceutical companies.

Explore further: In colorectal surgery, risk for blood clots appears higher with open method versus laparoscopy

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

In colorectal surgery, risk for blood clots appears higher with open method versus laparoscopy

June 20, 2011
The risk of developing venous thromboembolism (VTE) may be nearly twice as high for patients undergoing open surgery for colorectal problems, versus those undergoing laparoscopic colorectal (LC) resections, according to a ...

Early response is an indicator for rectal cancer survival

April 10, 2012
(HealthDay) -- In patients with locally advanced rectal cancer undergoing radical resection, response to neoadjuvant chemoradiotherapy is an early marker that correlates with rates of recurrence-free survival, distant metastases, ...

Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence

September 25, 2011
Stockholm, Sweden: A major UK trial has produced firm evidence that giving radiotherapy between or during chemotherapy cycles to women with early breast cancer significantly reduces the risk of the cancer recurring in the ...

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.